Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 134 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Sugar (Glucose) Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111
View directory record Official record
Conditions
Diabetes
Interventions
CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Determine the Effect of Synbiotics in Patients With Pre-diabetes

NCT04428606
View directory record Official record
Conditions
PreDiabetes
Interventions
Metabolic Rheostat, Butyrate Ultra, Placebo
Dietary Supplement
Lead sponsor
Zhaoping Li
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes

NCT01693302
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peanuts and Glycemic Control

NCT03654651
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Peanut, High carbohydrate snack
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

NCT05352815
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
110
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Whey Protein Effects on Gycemic Control and Vascular Function

NCT01814358
View directory record Official record
Conditions
Blood Sugar (Glucose) Control, Blood Vessel (Vascular) Dysfunction
Interventions
Whey protein powder, Control protein
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

NCT00484419
View directory record Official record
Conditions
Type 2 Diabetes, Hyperlipidemia
Interventions
Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Free Test Strips and Blood Glucose Control

NCT00205335
View directory record Official record
Conditions
Diabetes
Interventions
Ascencia Breeze Glucose meter, Breeze Glucose Monitor (Bayer)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Effectiveness of CGMS Vs. Self-monitoring Blood Glucose (SMBG) in Woman with Gestational Diabetes

NCT04948112
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy
Interventions
real time continuous glucose monitor, blinded continuous glucose monitor
Device
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Jul 21, 2026, 11:25 AM EDT
Completed No phase listed Observational

Sleep Disordered Breathing and Diabetes

NCT00901472
View directory record Official record
Conditions
Type 2 Diabetes, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

NCT01280695
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
14
States / cities
Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01407003
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Comparing Two Ways of Controlling Blood Sugar With Insulin in Patients Admitted to the Intensive Care Unit

NCT00166491
View directory record Official record
Conditions
Critical Illness, Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2011 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

NCT06323174
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Active, not recruiting Not applicable Interventional

Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose

NCT06208189
View directory record Official record
Conditions
PreDiabetes, Type 2 Diabetes Mellitus
Interventions
High-effort session, Low-effort session, Control
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Jul 21, 2026, 11:25 AM EDT
Active, not recruiting Not applicable Interventional

Circadian Health Regulation and Optimization for Rejuvenation Outcomes

NCT07203196
View directory record Official record
Conditions
Aging, Healthy, Blood Sugar; High, Blood Sugar (Glucose) Control, Time Restricted Eating, Circadian Dysregulation
Interventions
Circadian Rhythm Optimization
Behavioral
Lead sponsor
Salk Institute for Biological Studies
Other
Eligibility
50 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration

NCT06445569
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
KH-1, Placebo
Dietary Supplement · Other
Lead sponsor
Kalin Health, LLC
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CS-917, metformin hydrochloride, pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2007 · Synced Jul 21, 2026, 11:25 AM EDT
Suspended Not applicable Interventional

Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia

NCT04094649
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ultrasound Vagus Nerve Stimulation (DECIMA)
Device
Lead sponsor
Aucta Technologies, Inc.
Industry
Eligibility
21 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Jul 21, 2026, 11:25 AM EDT
Withdrawn Phase 2 Interventional

A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

NCT01067118
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
LINjeta U-100 Insulin, Humalog U-100
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Stanford, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Glucose and Motivation States

NCT07255183
View directory record Official record
Conditions
Motivation
Interventions
Exercise, Sugar Drink, Non-sugar beverage
Behavioral · Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Withdrawn Phase 4 Interventional

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

NCT00906529
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Levemir (Detemir) and Novolog (Aspart) Insulin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jul 21, 2026, 11:25 AM EDT